JP2006513184A5 - - Google Patents

Download PDF

Info

Publication number
JP2006513184A5
JP2006513184A5 JP2004560867A JP2004560867A JP2006513184A5 JP 2006513184 A5 JP2006513184 A5 JP 2006513184A5 JP 2004560867 A JP2004560867 A JP 2004560867A JP 2004560867 A JP2004560867 A JP 2004560867A JP 2006513184 A5 JP2006513184 A5 JP 2006513184A5
Authority
JP
Japan
Prior art keywords
buprenorphine
dosage form
administration
patient
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004560867A
Other languages
English (en)
Japanese (ja)
Other versions
JP5054893B2 (ja
JP2006513184A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/039792 external-priority patent/WO2004054553A1/en
Publication of JP2006513184A publication Critical patent/JP2006513184A/ja
Publication of JP2006513184A5 publication Critical patent/JP2006513184A5/ja
Application granted granted Critical
Publication of JP5054893B2 publication Critical patent/JP5054893B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004560867A 2002-12-13 2003-12-15 鎮痛のためのブプレノルフィン経皮投与計画 Expired - Fee Related JP5054893B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43342302P 2002-12-13 2002-12-13
US60/433,423 2002-12-13
PCT/US2003/039792 WO2004054553A1 (en) 2002-12-13 2003-12-15 Transdermal buprenorphine dosage regimen for analgesia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010182231A Division JP2010285457A (ja) 2002-12-13 2010-08-17 鎮痛のためのブプレノルフィン経皮投与計画

Publications (3)

Publication Number Publication Date
JP2006513184A JP2006513184A (ja) 2006-04-20
JP2006513184A5 true JP2006513184A5 (enExample) 2006-12-14
JP5054893B2 JP5054893B2 (ja) 2012-10-24

Family

ID=32595187

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004560867A Expired - Fee Related JP5054893B2 (ja) 2002-12-13 2003-12-15 鎮痛のためのブプレノルフィン経皮投与計画
JP2010182231A Withdrawn JP2010285457A (ja) 2002-12-13 2010-08-17 鎮痛のためのブプレノルフィン経皮投与計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010182231A Withdrawn JP2010285457A (ja) 2002-12-13 2010-08-17 鎮痛のためのブプレノルフィン経皮投与計画

Country Status (16)

Country Link
US (1) US7270830B2 (enExample)
EP (1) EP1572167B1 (enExample)
JP (2) JP5054893B2 (enExample)
AT (1) ATE400258T1 (enExample)
AU (2) AU2003297073A1 (enExample)
CA (1) CA2510223C (enExample)
CY (1) CY1108384T1 (enExample)
DE (1) DE60322102D1 (enExample)
DK (1) DK1572167T3 (enExample)
ES (1) ES2310262T3 (enExample)
IL (1) IL169056A (enExample)
MX (1) MXPA05006334A (enExample)
NZ (1) NZ539936A (enExample)
PT (1) PT1572167E (enExample)
SI (1) SI1572167T1 (enExample)
WO (1) WO2004054553A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU2003240493B2 (en) * 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
DE60322102D1 (de) * 2002-12-13 2008-08-21 Euro Celtique Sa Transdermales buprenorphin-dosierschema zwecks schmerzstillung
DE602004031512D1 (de) 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
AU2004235794B8 (en) * 2003-04-30 2009-07-23 Purdue Pharma L.P. Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
EA009921B1 (ru) * 2003-07-25 2008-04-28 Еуро-Селтик С.А. Способ лечения синдрома отвыкания от зависимости у беременных женщин
KR20120128715A (ko) * 2003-07-25 2012-11-27 유로-셀티큐 에스.에이. 수술후 통증의 수술전 치료
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
AU2006326377B2 (en) * 2005-12-13 2010-10-07 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
SI2054031T1 (sl) 2006-07-21 2016-09-30 Biodelivery Sciences International, Inc. Transmukozne naprave za administracijo z izboljšanim vnosom
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
US20110097395A1 (en) * 2008-03-08 2011-04-28 Najib Babul Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
US8741930B2 (en) * 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
SG10201610097WA (en) 2011-08-18 2017-01-27 Biodelivery Sciences Int Inc Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US20140363487A1 (en) * 2011-12-12 2014-12-11 Purdue Pharma L.P. Transdermal delivery system comprising buprenorphine
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
AP2015008920A0 (en) 2013-06-04 2015-12-31 Lohmann Therapie Syst Lts Transdermal delivery system
AU2017226830B2 (en) * 2016-02-29 2021-06-24 Grünenthal GmbH Titration of cebranopadol
WO2020124073A1 (en) * 2018-12-14 2020-06-18 Pear Therapeutics, Inc. A digital therapeutic component to optimize induction of buprenorphine-containing products

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA856002B (en) * 1984-08-10 1987-04-29 Du Pont Transdermal delivery of opioids
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
EP0484543B1 (en) 1990-04-24 1995-12-13 Teijin Limited Plaster
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
JP2886021B2 (ja) * 1993-03-19 1999-04-26 帝三製薬株式会社 安定な貼付剤
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
JP2837337B2 (ja) * 1993-08-10 1998-12-16 帝三製薬株式会社 貼付剤
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
JP3662388B2 (ja) * 1997-05-30 2005-06-22 日東電工株式会社 経皮吸収製剤及びその製造方法
DE60320770D1 (de) 2002-03-20 2008-06-19 Euro Celtique Sa Verfahren zur verabreichung von buprenorphin zur behandlung von depression
DE60322102D1 (de) * 2002-12-13 2008-08-21 Euro Celtique Sa Transdermales buprenorphin-dosierschema zwecks schmerzstillung
WO2004103317A2 (en) 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
EA009921B1 (ru) * 2003-07-25 2008-04-28 Еуро-Селтик С.А. Способ лечения синдрома отвыкания от зависимости у беременных женщин

Similar Documents

Publication Publication Date Title
JP2006513184A5 (enExample)
JP2007515469A5 (enExample)
JP2018507243A5 (enExample)
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
NO944565L (no) Preparat med regulert frigjörelse som inneholder et morfinsalt
JP2009544619A5 (enExample)
JP2005506367A5 (enExample)
JP2002532392A5 (enExample)
JP2009536147A5 (enExample)
JP2009501801A5 (enExample)
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
JP2012502103A5 (enExample)
JP2019529570A5 (enExample)
WO2005011579A3 (en) Treatment of dependence withdrawal
JP2009517411A5 (enExample)
JP2006514681A5 (enExample)
JP2016505050A5 (enExample)
JP2002540148A5 (enExample)
RU99119233A (ru) Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени
CA2563058A1 (en) Supportive treatment of liver disease
CA2435921A1 (en) Method of cancer therapy
KR101267771B1 (ko) 약제 조합을 이용한 치료 방법 및 이에 적합한 약제 조합
ES2184561A1 (es) Forma farmaceutica solida de administracion oral dispersable en agua para el tratamiento de la tuberculosis conteniendo refampicina, isoniazida, pirazinamida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
WO2007079195A3 (en) Gastric retentive gabapentin dosage forms and methods for using same